MetaVia Inc. (NASDAQ:MTVA – Free Report) – Analysts at HC Wainwright issued their FY2024 earnings estimates for shares of MetaVia in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will earn ($3.87) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.
MetaVia Price Performance
NASDAQ MTVA opened at $2.03 on Tuesday. MetaVia has a twelve month low of $1.51 and a twelve month high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- How to Invest in Small Cap StocksÂ
- 3 Stocks Helping to Bring AI to Healthcare
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- Stock Average Calculator
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
